Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celgene's CAR-T Leadership Goals Advance At ASH 2017

Executive Summary

Celgene's partnership strategy paid off at ASH with positive results for two CAR-T therapies in development with bluebird bio and Juno. The company is pursuing first- and best-in-class opportunities with the goal of becoming a leader in the CAR-T field.

Advertisement

Related Content

Top Drugs To Watch At ASH 2017: CAR-T, Venetoclax Among Highlights
Celgene's Partnered Pipeline Delivers Successes And Setbacks
Celgene Admits It Screwed Up Otezla Estimates; Investors Lose Confidence
Celgene IBD Pipeline In Question As Mongersen Crohn’s Disease Trial Ends
Gilead/Kite Pricing For Yescarta Undercuts Novartis's CAR-T Kymriah
Novartis Beats CAR-T Competitors To The Pricing Punch With Kymriah Approval
Bluebird Flies On 100% Response Rate For Anti-BCMA CAR-T
Too Sick For CAR-T? Kite Reports Cerebral Edema Death
Juno Ends JCAR015 Development In ALL, Cementing Third Place CAR-T Position
Companies focus on hard science, long-term pay-off at stem cell meeting

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100037

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel